CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,786,653 | +62.2% | 64,922 | +100.0% | 0.00% | +100.0% |
| Q2 2023 | $1,101,402 | -33.1% | 32,461 | -29.1% | 0.00% | -50.0% |
| Q1 2023 | $1,646,481 | -33.2% | 45,761 | -17.2% | 0.00% | -33.3% |
| Q4 2022 | $2,462,983 | +82.3% | 55,261 | +15.9% | 0.00% | +50.0% |
| Q3 2022 | $1,351,000 | +36.7% | 47,661 | +30.0% | 0.00% | +100.0% |
| Q2 2022 | $988,000 | -60.7% | 36,661 | -50.3% | 0.00% | -50.0% |
| Q1 2022 | $2,515,000 | +4.4% | 73,829 | +18.5% | 0.00% | 0.0% |
| Q4 2021 | $2,408,000 | -28.4% | 62,329 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $3,365,000 | +71.2% | 62,329 | +38.7% | 0.00% | +50.0% |
| Q2 2021 | $1,966,000 | +317.4% | 44,929 | +96.6% | 0.00% | +100.0% |
| Q1 2021 | $471,000 | +64.1% | 22,850 | +39.3% | 0.00% | – |
| Q4 2020 | $287,000 | – | 16,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 761,398 | $41,108,000 | 10.12% |
| Opaleye Management Inc. | 985,000 | $53,045,000 | 9.91% |
| VR Adviser, LLC | 1,098,174 | $59,290,000 | 7.62% |
| ACUTA CAPITAL PARTNERS, LLC | 337,500 | $18,222,000 | 6.43% |
| TSP Capital Management Group, LLC | 271,429 | $14,654,000 | 5.00% |
| Ghost Tree Capital, LLC | 255,000 | $13,767,000 | 4.03% |
| COMMODORE CAPITAL LP | 248,207 | $13,401,000 | 3.53% |
| RTW INVESTMENTS, LP | 3,908,947 | $211,044,000 | 3.18% |
| Ikarian Capital, LLC | 791,600 | $42,741,000 | 3.01% |
| Redmile Group, LLC | 3,043,298 | $164,308,000 | 2.87% |